Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501860 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution
A Phase 3 study, sponsored by American Genomics.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT05501860: Completed Phase 3 study, sponsored by American Genomics.
NCT05501860 is a Phase 3 study that has completed, run by American Genomics. The registered enrollment target is 249 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501860, a Phase 3 study, has completed, sponsored by American Genomics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
Primary Outcome
TEAEs will be summarized by treatment group using frequency and percent for each system, organ, class (SOC) and preferred term within each SOC.
Interventions
- DRUG Placebo
- DRUG AG-920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2022-07-30 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 3 |
What the finished NCT05501860 record still lists
NCT05501860 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05501860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05501860 about?
NCT05501860 is a clinical study titled "A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution". A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..
What is the current status of trial NCT05501860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2022-07-30. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT05501860?
The interventions under investigation include: Placebo (DRUG), AG-920 (DRUG).
Who is sponsoring clinical trial NCT05501860?
This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05501860's enrollment target sits among peer trials
249 1266th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI